VK-2019 for Nasopharyngeal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing VK 2019, a new cancer treatment, on patients with a specific type of throat cancer linked to the Epstein-Barr virus who have no other treatment options. The goal is to see if VK 2019 can effectively fight the cancer and to understand its safety and effects on patients.
Will I have to stop taking my current medications?
The trial requires that you do not take any other systemic cancer treatments, including complementary or alternative therapies, while participating. It does not specify about other medications, so you should discuss your current medications with the trial team.
What safety data exists for VK-2019 in humans?
How does the drug VK-2019 work differently from other treatments for nasopharyngeal cancer?
What data supports the effectiveness of the drug VK-2019 for treating nasopharyngeal cancer?
Research shows that VK-2019 is a specific inhibitor of EBNA1, a protein critical for the maintenance of the Epstein-Barr virus in cancer cells. Similar EBNA1 inhibitors have shown strong anti-cancer effects in models of other Epstein-Barr virus-associated cancers, suggesting potential effectiveness for nasopharyngeal cancer.12378
Who Is on the Research Team?
A. Dimitrios Colevas
Principal Investigator
Stanford Universiy
Are You a Good Fit for This Trial?
Adults with EBV-positive nasopharyngeal cancer not eligible for standard treatments can join. They must have good kidney function, controlled protein in urine, agree to birth control use, and be generally well enough (ECOG ≤2). Prior treatments should be completed with recovered side effects (except stable chronic issues), and blood counts need to meet specific levels.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VK 2019 in cycles of 28 days, up to 12 cycles, until progression or dose limiting toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Participants may continue to be monitored for overall survival and progression-free survival
What Are the Treatments Tested in This Trial?
Interventions
- VK-2019
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Cancer Institute (NCI)
Collaborator